CRVS
Corvus Pharmaceuticals, Inc.
NASDAQ · Healthcare · Biotechnology · US
$9.65
+1.37%Next report
Analyst consensus
- Next report date
- Nov 3, 2026
- EPS estimate
- -$0.19
- Revenue estimate
- —
Latest reported
- Last report date
- Aug 6, 2026
- EPS actual
- -$0.19
- EPS estimate
- -$0.16
- Revenue actual
- —
- Revenue estimate
- —
Track record
Trailing twelve quarters
- EPS beats (12Q)
- 2
- EPS misses (12Q)
- 7
- EPS in line (12Q)
- 3
- Avg surprise (4Q)
- -7.0%
- Revenue beats (12Q)
- —
Reported history
| Report date | EPS estimate | EPS actual | Surprise | Revenue actual |
|---|---|---|---|---|
| Aug 6, 2026 | -$0.16 | -$0.19 | Miss -19.41% | — |
| May 14, 2026 | -$0.14 | -$0.15 | Miss -7.14% | — |
| Mar 12, 2026 | -$0.13 | -$0.15 | Miss -15.89% | — |
| Nov 4, 2025 | -$0.14 | -$0.12 | Beat 14.29% | — |
| Aug 7, 2025 | -$0.13 | -$0.10 | Beat 23.08% | — |
| May 8, 2025 | -$0.13 | -$0.13 | In line | — |
| Mar 25, 2025 | -$0.12 | -$0.18 | Miss -50.00% | — |
| Mar 19, 2024 | -$0.14 | -$0.14 | In line | $246.0K |
| Nov 3, 2022 | -$0.16 | -$0.32 | Miss -100.00% | — |
| May 5, 2022 | -$0.14 | -$0.18 | Miss -28.57% | — |
| Mar 10, 2022 | -$0.20 | -$0.20 | In line | — |
| Apr 29, 2021 | -$0.33 | -$0.34 | Miss -3.03% | — |
Reported results against consensus at the time of each report · Surprise is computed from the estimate on record · Data as of Nov 3, 2026